SCHEMBL13166647

SCHEMBL13166647

O=[N+]([O-])c1ccc(Oc2ccnc3cc(-c4ccccc4)sc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
LMNA P02545 3/20 0.43
KDR P35968 3/20 0.43
PDGFRA P16234 2/20 0.43
ALDH1A1 P00352 3/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RAB9A P51151 2/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 1/20 0.40
IKBKB O14920 1/20 0.40
APP P05067 1/20 0.40
CHEK2 O96017 1/20 0.39
HSPB1 P04792 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3572691 0.89 PDGFRA (0.44) MAPTLMNAKDRPDGFRAALDH1A1
SCHEMBL2285415 0.82 IKBKB (0.50) MAPTLMNAKDRALDH1A1KMT2A
SCHEMBL3560063 0.81 PDGFRA (0.46) MAPTLMNAKDRPDGFRAALDH1A1
SCHEMBL13166636 0.81 KDR (0.48) MAPTLMNAKDRPDGFRAALDH1A1
SCHEMBL3576979 0.80 MET (0.52) KDRMET
SCHEMBL3569398 0.79 LTA4H (0.49) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL12754691 0.77 APP (0.46) MAPTLMNAKDRALDH1A1KMT2A
SCHEMBL306754 0.77 MET (0.43) KDRHSPB1MET
SCHEMBL3567574 0.77 MET (0.45) MAPTKDRKMT2AMEN1RAB9A
SCHEMBL3566804 0.75 MET (0.42) KDRHSPB1MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470850-B2 Inhibitors of VEGF receptor and HGF receptor signalling METHYLGENE INC. (CA) 2013-06-25 US disclosed
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 US disclosed
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling 92229129 QUEBEC INC. (CA) 2010-08-26 US disclosed
US-7772247-B2 Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor METHYLGENE INC. (CA) 2010-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling HGF, MET, FLT1 MAPT 2430/4885LMNA 4411/4885KDR 4/4885
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling HGF, MET, FLT1 MAPT 2320/4885LMNA 4480/4885KDR 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.